ReviewImmunological reviews2025
Thymic Dendritic Cells Revisited.
Review in Immunological reviews, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Advances in Immunotherapy for Intrahepatic Cholangiocarcinoma.International journal of molecular sciences · 2026Review
- Thymus and Leishmania at the Crossroads: Autoimmunity and Cancer.Immunology · 2026Review
- Thymic Dendritic Cells Revisited.Immunological reviews · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Central tolerance in the thymus ensures that the developing T cell repertoire is safe yet effective against infections. This process relies greatly on antigen presentation by both stromal and hematopoietic antigen-presenting cells (APCs), with dendritic cells (DCs) playing a particularly critical role. Thymic DCs acquire a broad spectrum of self-antigens, including tissue-restricted antigens (TRAs), inflammation-associated antigens (ISAs), and peripheral antigens imported via circulation or immigrating DCs. These diverse inputs allow DCs to mediate clonal deletion, regulatory T cell (Treg) induction, and other agonist selection outcomes. In this review, we revisit thymic DCs, outlining their ontogeny, transcriptional control, and functional specialization. We compare thymic DC1 and DC2 subsets with their peripheral counterparts, highlighting their distinct localizations, maturation cues, and division of labor: DC1 excel in cross-presentation and Treg generation, while DC2 preferentially drive clonal deletion. We also highlight the heterogeneity of DC2s, which consist of four distinct subsets based on their transcriptional and phenotypic programs. We further examine plasmacytoid DCs, transitional DCs, monocytes, and macrophages, which contribute to tolerance through apoptotic cell clearance, antigen transfer, and lineage diversion of thymocytes. Finally, we discuss the role of homeostatic maturation, sterile inflammatory cues, and thymic immigration in shaping APC diversity. Together, these insights underscore the heterogeneity of thymic APCs, the complexity of thymic DC biology, and its vital importance in enforcing immune self-tolerance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.